Jennifer S. Michaelson

4.8k total citations
66 papers, 3.9k citations indexed

About

Jennifer S. Michaelson is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Jennifer S. Michaelson has authored 66 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Immunology, 26 papers in Molecular Biology and 24 papers in Oncology. Recurrent topics in Jennifer S. Michaelson's work include NF-κB Signaling Pathways (22 papers), Monoclonal and Polyclonal Antibodies Research (18 papers) and CAR-T cell therapy research (15 papers). Jennifer S. Michaelson is often cited by papers focused on NF-κB Signaling Pathways (22 papers), Monoclonal and Polyclonal Antibodies Research (18 papers) and CAR-T cell therapy research (15 papers). Jennifer S. Michaelson collaborates with scholars based in United States, Germany and Switzerland. Jennifer S. Michaelson's co-authors include Linda C. Burkly, Philip Leder, Timothy S. Zheng, Chaim Putterman, Aniela Jakubowski, Beth Browning, Kyungmin Hahm, Noa Schwartz, Barbara K. Birshtein and Christine A. Kozak and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Jennifer S. Michaelson

63 papers receiving 3.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer S. Michaelson United States	33	2.2k	1.5k	1.3k	766	580	66	3.9k
Thierry Rème France	43	2.5k 1.2×	1.8k 1.2×	532 0.4×	1.4k 1.9×	292 0.5×	102	5.4k
Lars H. Engelholm Denmark	31	1.3k 0.6×	571 0.4×	1.2k 0.9×	1.1k 1.4×	157 0.3×	79	3.4k
Annelise Bennaceur‐Griscelli France	36	3.3k 1.5×	840 0.6×	475 0.4×	1.2k 1.5×	1.0k 1.7×	131	6.3k
Roy A. Fava United States	24	1.5k 0.7×	1.6k 1.1×	383 0.3×	1.1k 1.5×	608 1.0×	35	4.0k
Jacqueline Doody United States	23	5.2k 2.4×	421 0.3×	552 0.4×	1.6k 2.0×	350 0.6×	34	6.5k
Wolfgang F. Vogel Canada	34	2.4k 1.1×	767 0.5×	550 0.4×	1.2k 1.6×	224 0.4×	49	5.0k
Brett M. Hall United States	22	2.0k 0.9×	698 0.5×	1.0k 0.8×	2.1k 2.8×	211 0.4×	43	4.7k
Reuben Kapur United States	41	2.8k 1.3×	2.4k 1.6×	568 0.4×	932 1.2×	370 0.6×	172	6.0k
Jinlu Dai United States	33	2.1k 1.0×	677 0.5×	856 0.6×	2.4k 3.1×	215 0.4×	58	4.5k
Johan Lennartsson Sweden	31	1.8k 0.8×	880 0.6×	321 0.2×	715 0.9×	179 0.3×	76	3.5k

Countries citing papers authored by Jennifer S. Michaelson

Since Specialization

Citations

This map shows the geographic impact of Jennifer S. Michaelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer S. Michaelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer S. Michaelson more than expected).

Fields of papers citing papers by Jennifer S. Michaelson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer S. Michaelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer S. Michaelson. The network helps show where Jennifer S. Michaelson may publish in the future.

Co-authorship network of co-authors of Jennifer S. Michaelson

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer S. Michaelson. A scholar is included among the top collaborators of Jennifer S. Michaelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer S. Michaelson. Jennifer S. Michaelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Henry, Cathérine, Naveen K. Mehta, Kavya Rakhra, et al.. (2025). CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity. Journal for ImmunoTherapy of Cancer. 13(4). e008987–e008987. 2 indexed citations

Mehta, Naveen K., Kavya Rakhra, Kristan Meetze, et al.. (2024). CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity. Cancer Immunology Research. 12(8). 1022–1038. 6 indexed citations

Michaelson, Jennifer S. & Patrick A. Baeuerle. (2024). CD19-directed T cell–engaging antibodies for the treatment of autoimmune disease. The Journal of Experimental Medicine. 221(5). 3 indexed citations

Meetze, Kristan, Naveen K. Mehta, Bochong Li, et al.. (2023). CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression. Journal for ImmunoTherapy of Cancer. 11(8). e007398–e007398. 11 indexed citations

Rakhra, Kavya, et al.. (2023). Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors. mAbs. 15(1). 21 indexed citations

Ioffe, Ella, Naveen K. Mehta, Kristan Meetze, et al.. (2023). 1171 CLN-418, a clinical-stage B7H4 x 4–1BB bispecific antibody with potential to treat patients with a wide range of solid tumors. SHILAP Revista de lepidopterología. A1291–A1291.

Elpek, Kutlu G., Ellen Duong, Martin Fan, et al.. (2020). ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS ONE. 15(9). e0239595–e0239595. 23 indexed citations

Elpek, Kutlu G., Christopher J. Harvey, Ellen Duong, et al.. (2016). Abstract A059: Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. Cancer Immunology Research. 4(1_Supplement). A059–A059. 1 indexed citations

Michaelson, Jennifer S., et al.. (2012). The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models. Cancer Biology & Therapy. 13(9). 812–821. 21 indexed citations

10.

Michaelson, Jennifer S., Aldo Amatucci, Rebecca K. Kelly, et al.. (2011). Development of an Fn14 agonistic antibody as an anti-tumor agent. mAbs. 3(4). 362–375. 38 indexed citations

11.

Burkly, Linda C., Jennifer S. Michaelson, & Timothy S. Zheng. (2011). TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunological Reviews. 244(1). 99–114. 175 indexed citations

12.

Schwartz, Noa, Tamar B. Rubinstein, Linda C. Burkly, et al.. (2009). Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Research & Therapy. 11(5). R143–R143. 149 indexed citations

13.

Campbell, Sean R., Linda C. Burkly, Aniela Jakubowski, et al.. (2009). TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine. 46(1). 24–35. 100 indexed citations

14.

Zhao, Zeguo, Linda C. Burkly, Sean Campbell, et al.. (2007). TWEAK/Fn14 Interactions Are Instrumental in the Pathogenesis of Nephritis in the Chronic Graft-versus-Host Model of Systemic Lupus erythematosus. The Journal of Immunology. 179(11). 7949–7958. 127 indexed citations

15.

Burkly, Linda C., Jennifer S. Michaelson, Kyungmin Hahm, Aniela Jakubowski, & Timothy S. Zheng. (2007). TWEAKing tissue remodeling by a multifunctional cytokine: Role of TWEAK/Fn14 pathway in health and disease. Cytokine. 40(1). 1–16. 234 indexed citations

16.

Schwartz, Noa, Jennifer S. Michaelson, & Chaim Putterman. (2007). Lipocalin‐2, TWEAK, and Other Cytokines as Urinary Biomarkers for Lupus Nephritis. Annals of the New York Academy of Sciences. 1109(1). 265–274. 60 indexed citations

17.

Tran, Nhan L., Wendy S. McDonough, Benjamin A. Savitch, et al.. (2006). Increased Fibroblast Growth Factor-Inducible 14 Expression Levels Promote Glioma Cell Invasion via Rac1 and Nuclear Factor-κB and Correlate with Poor Patient Outcome. Cancer Research. 66(19). 9535–9542. 163 indexed citations

18.

Campbell, Sean, Linda C. Burkly, Joan W. Berman, et al.. (2006). Proinflammatory Effects of Tweak/Fn14 Interactions in Glomerular Mesangial Cells. The Journal of Immunology. 176(3). 1889–1898. 143 indexed citations

19.

Schwartz, Noa, Lihe Su, Linda C. Burkly, et al.. (2006). Urinary TWEAK and the activity of lupus nephritis. Journal of Autoimmunity. 27(4). 242–250. 112 indexed citations

20.

Birshtein, Barbara K., et al.. (1997). Murine and Human 3′ IgH Regulatory Sequences. Current topics in microbiology and immunology. 224. 73–80. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact